Table 4.
APD changes after FCCP application in the presence of the various inhibitors.
| APD20 (%) | APD50 (%) | APD90 (%) | |
|---|---|---|---|
| Control (n = 18) | |||
| FCCP↑ | 4.7 ± 0.8* | 8.8 ± 0.7* | 11.7 ± 0.8* |
| FCCP 2.5′ | –30.1 ± 2.9* | –27.6 ± 3.4* | –21.9 ± 3.3* |
| FCCP 5′ | –65.7 ± 4.9* | –64.3 ± 4.6* | –53.9 ± 4.0* |
| DTZ (n = 4) | –10.9 ± 1.7# | –11.4 ± 0.5# | –9.7 ± 0.3# |
| DTZ + FCCP↑ | –0.4 ± 0.8† | 3.1 ± 0.8*† | 5.2 ± 0.6*† |
| styDTZ + FCCP 2.5′ | –21.3 ± 1.4* | –19.6 ± 0.9* | –17.2 ± 0.9* |
| DTZ + FCCP 5′ | –71.8 ± 1.6* | –71.0 ± 1.8* | –61.7 ± 2.6* |
| Ranolazine (n = 4) | 0.6 ± 1.6 | 1.1 ± 0.5# | 2.3 ± 0.3# |
| Ran + FCCP↑ | 5.7 ± 1.6* | 8.6 ± 0.8* | 10.1 ± 0.8* |
| Ran + FCCP 2.5′ | –29.3 ± 6.9* | –31.8 ± 7.2* | –26.3 ± 6.1* |
| Ran + FCCP 5′ | –63.0 ± 9.3* | –63.0 ± 9.7* | –54.6 ± 9.9* |
| 4-AP (n = 8) | 20.8 ± 2.3# | 20.3 ± 2.1# | 17.0 ± 1.3# |
| 4-AP + FCCP↑ | 3.8 ± 0.8* | 7.3 ± 1.0* | 9.1 ± 1.0*† |
| 4-AP + FCCP 2.5′ | –41.9 ± 5.4* | –43.1 ± 4.8*† | –36.0 ± 4.1*† |
| 4-AP + FCCP 5′ | –69.3 ± 5.1* | –71.2 ± 4.9* | –66.1 ± 5.0* |
| Oligomycin (n = 4) | 3.3 ± 1.4 | 2.3 ± 1.2 | 2.1 ± 1.2 |
| Oligo + FCCP↑ | 0.8 ± 0. 3† | 1.7 ± 0.4† | 2.9 ± 0.3† |
| Oligo + FCCP 2.5′ | –1.8 ± 1.3† | –0.3 ± 0.3† | 1.8 ± 0.2† |
| Oligo + FCCP 5′ | –13.4 ± 3.1† | –9.6 ± 1.2† | –5.2 ± 0.5† |
Diltiazem (DTZ, 10 μmol/L) – L-type calcium channel blocker, ranolazine (Ran, 10 μmol/L) – late sodium channel blocker, 4-aminopyridine (4-AP, 2 mmol/L) – a transient outward K+ channel blocker, oligomycin A (Oligo, 30 μmol/L) – a mitochondrial F1F0ATPase inhibitor. The positive and negative percentages show prolongation and shortening of APs, respectively. Other notations are the same as in Table 1. ∗p < 0.05 with FCCP vs. before FCCP treatment. #p < 0.05 drug (DTZ, Ran, 4-AP, Oligo) vs. control (see Table 1). †p < 0.05 drug+FCCP vs. FCCP alone values obtained at the same time of FCCP action.